

May 19, 2025

The Manager, Listing Department  
The National Stock Exchange of India Ltd.  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: PANACEABIO

BSE Limited  
Corporate Relationship Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001  
BSE Scrip Code: 531349

**Re.: Press Release - Nation-Wide Study Confirms ChilRun full Accelerates Growth and Development in Children, in just 90 days**

Dear Sir/Madam,

This is to inform you that the Company's material subsidiary viz., Panacea Biotec Pharma Limited's ("PBPL") scientifically formulated oral nutritional supplement - ChilRun full has demonstrated considerable success in enhancing childhood growth, especially among ones at risk of malnutrition, according to the results of a comprehensive 90-day nationwide post-marketing observational study, conducted by PBPL.

A copy of the Press Release titled "**Nation-Wide Study Confirms ChilRun full Accelerates Growth and Development in Children, in just 90 days**" being issued to the media, etc. in this regard is enclosed for your kind reference and record please.

Kindly acknowledge the receipt.

Thanking you,

Sincerely yours,

for **Panacea Biotec Limited**

**Vinod Goel**  
**Group CFO and Head Legal**  
**& Company Secretary**

Encl. As Above

## Nation-Wide Study Confirms ChilRun full Accelerates Growth and Development in Children, in just 90 days

May 19, 2025 at New Delhi:

Panacea Biotec Pharma Limited's scientifically formulated oral nutritional supplement - ChilRun full has demonstrated considerable success in enhancing childhood growth, especially among ones at risk of malnutrition, according to the results of a comprehensive 90-day nationwide post-marketing [observational study](#), conducted by Panacea Biotec.



Childhood malnutrition continues to affect one in three children globally, particularly in India, where 35% of children under five are stunted and 19% are wasted (NFHS-5). Hidden hunger, micronutrient deficiency, remains a major contributor, silently impairing brain development, immunity, and physical growth.

**Dr. Rajesh Jain, Managing Director, Panacea Biotec Pharma says,** “At Panacea Biotec, we are committed to improving child health with science-led, evidence-backed innovations. This study reinforces the vital role of ChilRun full in bridging the nutrition gap in growing children. It's about giving every child the chance to grow

up healthy, energetic and strong. Panacea Biotec is dedicated to enabling people to live well and live longer; we see ChilRun full as a transformative tool in pediatric nutrition and in the fight against malnutrition.”

As global and national efforts accelerate to address childhood malnutrition, total nutrition products like ChilRun full are poised to play a central role. Backed by rigorous data and clinical outcomes, ChilRun full provides a strong nutritional foundation for **Healthy, Energetic and Strong Kids**.

**Key Highlights of the study:** The post-marketing observational study evaluated the safety and efficacy of ChilRun full, administered twice daily over 90 days. Anthropometric data (height, weight, BMI) was collected at four intervals (Day 0, 30, 60 and 90) under supervision of several well known pediatricians.

### **Panacea Biotec Pharma Limited**

CIN: U24299DL2019PLC347566

Registered Office: B-1 Extn./A-27 Mohan Co-operative Industrial Estate, Mathura Road, New Delhi-110044, India.

Ph.:+91-41578000; e-mail: pharma@panaceabiotec.com

- 2,851 children aged 2+ years participated across 282 clinics in 32 Indian cities
- Continuous supplementation with ChilRun full (twice a day for 90 days) led to significant improvements in height, weight and BMI across all age groups
- Up to 20.56% weight gain observed in undernourished children
- 111 boys and 73 girls moved upward to a healthier weight range from the original growth curve.

**About ChilRun full: *See your child grow in 90 days***

ChilRun full is a scientifically formulated oral nutritional supplement, designed to be an additional source of nutrition to overcome the nutrition gap for growing children. ChilRun full provides 37 essential nutrients including protein, healthy fats, and carbohydrates with vitamins and minerals (such as Calcium, Phosphorus, Iron, Iodine, Magnesium, Chloride, Sodium, Potassium, Manganese, Molybdenum, Chromium, Vitamin D, Zinc, Copper, Selenium, Vitamin A, Vitamin C, Vitamin E, Vitamin K1, Vitamin K2, B-complex including Vitamin B1, Vitamin B2, Vitamin B6, Vitamin B12, Folic acid, Niacin, Pantothenic acid, Biotin), Probiotics (*Lactobacillus acidophilus*) & also Inositol, Taurine, L-Carnitine, & Choline. These components support endocrine function, enhance cognitive development, bone health, and strengthen immunity, while also improving gut health through the microbiome. ChilRun full is available in 4 tasty flavours: Chocolate, Mango, Vanilla, and Kesar Badam. For parents concerned about sugar intake, ChilRun full No Sucrose provides the same benefits with zero table sugar.

ChilRun full, ChilRun full No Sucrose, and ChilRun 7+ are available on [www.7nshop.com](http://www.7nshop.com) along with online retailers like Amazon, Flipkart, Tata 1mg, etc. It is also available at a retailer near you!

**About Panacea Biotec**

Panacea Biotec Limited is a leading pharmaceutical and biotechnology company with established research, manufacturing and marketing capabilities.

Panacea Biotec's wholly-owned subsidiary, Panacea Biotec Pharma Limited has pioneered in the development of innovative fully-liquid combination vaccines that can be stored at 2-8 degree Celsius temperature.

Panacea Biotec has also launched the world's first fully liquid wP-IPV based hexavalent vaccine EasySix™ (DTwP-HepB-Hib-IPV) in India in March 2017. We have made available over 200 million doses of fully-liquid combination vaccines across the world.

**Panacea Biotec Pharma Limited**

CIN: U24299DL2019PLC347566

Registered Office: B-1 Extn./A-27 Mohan Co-operative Industrial Estate, Mathura Road, New Delhi-110044, India.

Ph.:+91-41578000; e-mail: [pharma@panaceabiotec.com](mailto:pharma@panaceabiotec.com)

The other key vaccines in portfolio are Easyfive-TT (DTwP-HepB-Hib), EasyFour-TT (DTwP-Hib), IPV based tetravalent vaccine – EasyFour-Pol (DTwP-IPV) and Bivalent oral polio vaccine (type-1 and type-3). Panacea Biotec’s new vaccines in pipeline are Pneumococcal Conjugate Vaccine - NucoVac-11 and Recombinant Tetravalent Dengue Candidate Vaccine - DengiALL and India’s first thiomersal free Td (tetanus and diphtheria – reduced).

**For media queries, please contact:**

**1. Mr. P. D. Karan**

Sr. Vice President - Business Development & Corporate Affairs  
Tel: +91-11-41679000 Ext. 1406, 41578080 (Direct)  
Mobile: +91 9312693040, +91 9810500539  
Email: [pdkaran@panaceabiotec.com](mailto:pdkaran@panaceabiotec.com)

**2. Ms. Geetanjali Grover**

Sr. Manager - Corporate Communications  
Tel: +91-11-41679000 Ext. 1414  
Mobile: +91 99100 32288  
Email: [geetanjali@panaceabiotec.com](mailto:geetanjali@panaceabiotec.com)

**Panacea Biotec Pharma Limited**

CIN: U24299DL2019PLC347566

Registered Office: B-1 Extn./A-27 Mohan Co-operative Industrial Estate, Mathura Road, New Delhi-110044, India.  
Ph.:+91-41578000; e-mail: [pharma@panaceabiotec.com](mailto:pharma@panaceabiotec.com)